The company states: "Teva Pharmaceutical (TEVA) announced that the FDA has issued a complete response letter to its partner Alvotech (ALVO) for the Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira(R) (adalimumab). The CRL stated that the application could not be approved at this time based on deficiencies associated with Alvotech’s manufacturing facility that must be satisfactorily resolved. Additional review of the details following the recent FDA’s re-inspection and CRL are being assessed to determine next steps. While this outcome is disappointing, Teva remains fully committed to its leadership in biosimilars and the partnership with Alvotech. The Company remains optimistic about additional compounds in the pipeline and further progress with AVT02."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALVO:
- Alvotech Provides Regulatory Update on AVT02 Biologics License Application
- Alvotech Provides Update on Corporate Sustainability Framework
- Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
- Alvotech to present clinical study data for AVT04 at AAD Annual Meeting
- Alvotech price target raised to $12 from $8 at Deutsche Bank
